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Updates for the District of Columbia:
A er decreases in community spread in May and early June, recent increases in cases have been
●
reported in the District and in Maryland. It remains to be seen if this trend con nues, and whether it
will aﬀect DC’s ability to enter Phase 2 (currently scheduled for 19JUNE).
Following mass demonstra ons for racial jus ce and police reform, the Mayor recommended
●
a endees self-isolate at home and seek tes ng. Long waits are reported and new sites have opened.
Hospital occupancy is at 80.5% in DC, the highest since April, but the propor on of occupancy due to
●
COVID-19 is down and ven lator u liza on remains <50%.
Disease burden con nues to dispropor onately aﬀect Black residents (50% of cases, 74% of deaths).
●
Key updates in preven on of COVID-19:
Further evidence supports airborne droplet spread as the main modality of SARS-CoV-2 transmission,
●
and suggests that mandated use of face masks in public was associated with signiﬁcant reduc ons in
transmission in China, Italy, and New York, preven ng tens of thousands of new infec ons.
On 12JUNE the CDC released general public guidance for reducing the risk of COVID-19 based on
●
ac vi es, loca on, and risk factors.
Key updates in treatment for COVID-19:
Although previous inves ga on of lopinavir/ritonavir in hospitalized pa ents with COVID-19 failed to
●
show a clinical beneﬁt, a new study suggests it may be associated with faster viral clearance in nonsevere pa ents with higher lymphocyte counts. Unclear if this is by way of associa on or causa on.
A systema c review of 18 ar cles, of which only 5 were RCTs, found wide heterogeneity of data
●
regarding the safety and eﬃcacy of lopinavir/ritonavir, ribavirin, and other an virals.
Acalabru nib (inhibitor of Bruton tyrosine kinase which regulates macrophage ac va on) showed
●
improvement in measures of inﬂamma on and oxygena on in a small group with severe COVID-19.
Ongoing treatment with RAAS inhibitors (ACEis/ARBs) was not associated with increased mortality in
●
pa ents presen ng for hospital care, and might be beneﬁcial, based on studies in Italy and in China.
Nine studies of mesenchymal stromal (stem) cells as treatment for COVID-19-associated ARDS did not
●
show a sta s cally signiﬁcant beneﬁt but might suggest this as an area for future explora on.
The NIH has updated its COVID-19 Treatment Guidelines to recommend against the use of chloroquine
●
or hydroxychloroquine outside of trials, and the FDA has revoked its Emergency Use Authoriza on.
Updates on obstetric, pediatric, inﬂammatory, and severe disease complica ons:
A systema c review iden ﬁed 13 papers including 538 pregnancies complicated by COVID-19. The
●
reported rates of maternal cri cal illness was low (1.4%; no mortali es), preterm birth rate was 20%, Csec on rate was 85%, ver cal transmission rate was 0%, and neonatal death rate was 0.3%.
In children presen ng with COVID-19, co-infec on with other respiratory pathogens may be common
●
(51% of 74 pediatric pa ents had 1 or more co-pathogen; 42% had 2 or more co-pathogens).
Evidence on PIMS or MIS-C con nues to build, with 58 cases reported from the UK and 156 from
●
France. In one report of 21 pa ents in Paris, there was a possible associa on with African ancestry.
Cardiac ﬁndings in pa ents with MIS-C in NY included ST/T-wave abnormali es, dysrhythmias (PVCs,
●
NSVT, sinus bradycardia), and ventricular dysfunc on. These may warrant long-term monitoring.
A study of pulmonary func on tests in adult survivors of severe COVID-19 performed at hospital
●
discharge and 2 weeks later found persistent deﬁcits in VC, FVC, FEV1, and FEV1/FVC.
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PRE-PRINT: In a study of outcomes in 17 million adult COVID-19 pa ents in the UK NHS, mortality was
higher among Asian and Black pa ents, and this was not fully explained by pre-exis ng clinical factors.

Updates on systems of care:
FDA has issued an updated Emergency Use Authoriza on guide to which types of respirators can be
●
safely decontaminated and reused. See here for a reminder on safe donning and doﬃng of PPE.
The Joint Commission published ps on promo ng well-being of health care staﬀ during crisis including
●
removal inhibit clinicians and health care staﬀ from accessing mental health care.
The Johns Hopkins Center for Health Security has published recommenda ons for improving na onal
●
nursing preparedness for pandemic response based on the experience with COVID-19.
The risks of endotracheal intuba on of pa ents with COVID-19 to HCP were studied using simula ons
●
involving ﬂuorescent dye and diﬀerent types of protec on. In another study, 10% of exposed HCP
subsequently reported possible symptoms, though diagnos c tests were not consistently performed.
Among ICU and Anesthesiology personnel in Columbia University Hospital, 12% tested posi ve for
●
an bodies to COVID-19, but it was unclear if this was due to workplace exposure or the NYC subway.
The World Health Organiza on published a Q&A on masks that can be used as a pa ent resource.
●
Two papers in Nature reviewed the impact of large-scale societal restric ons on reducing the spread of
●
COVID-19 across mul ple countries and regions. Without policy ac ons, early infec ons of COVID-19
grew by ~38% per day, while an -contagion policies signiﬁcantly slowed this growth. Across 11
European countries, such interven ons were suﬃcient to drive Rt <1 and achieve epidemic control.
Cau on in interpre ng preliminary data releases:
Rapid publica on of preliminary ﬁndings on COVID-19 has been plagued by errors and
●
misunderstandings, and has not proven to advance development of eﬀec ve therapeu cs.
Of clinical trials registered early in the pandemic, a large propor on was poorly designed, did not have
●
clinically relevant endpoints, or combined interven ons in ways that stymied interpreta on.
As an example of the la er, in a study of umifenovir (Arbidol) in China, 62 pa ents received mul ple
●
experimental treatments and one arm also received the study drug. Pa ents who received umifenovir
reported earlier of resolu on of symptoms but there was no signiﬁcant diﬀerence in the LOS.
This JAMA viewpoint published in April provides further context for the challenge of preserving
●
scien ﬁc integrity and public conﬁdence in the face of pressure to approve new treatments.
This is illustrated by the recent high-proﬁle retrac ons of the NEJM paper on cardiovascular disease
●
treatment and the Lancet paper on hydroxychloroquine, which were retracted as the Surgisphere
database was not made available for independent audit.
Non-interven onal studies can be aﬀected by the pressure to publish as well. One example is a study
●
claiming aerosolized spread of COVID-19 on public transit which has now been retracted. (For context
on aerosols, this MGH FLARE report remains relevant as does this Lancet paper.)
This report was produced by Dr. Hana Akselrod, Stacy Brody (Himmelfarb Librarian) and the GW Covid-19
Intelligence Unit. If you have a ques on that the Intelligence Unit can assist you with, or if you would like to
provide sugges ons or feedback, please email Dr. Lawrence “Bopper” Deyton, lead for the Intelligence Unit, at
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